Cancer Cell International (Sep 2021)

Recombinant immunotoxins development for HER2-based targeted cancer therapies

  • Reza Mahmoudi,
  • Hassan Dianat-Moghadam,
  • Mansour Poorebrahim,
  • Samaneh Siapoush,
  • Vahdat Poortahmasebi,
  • Reza Salahlou,
  • Mohammad Rahmati

DOI
https://doi.org/10.1186/s12935-021-02182-6
Journal volume & issue
Vol. 21, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Understanding the molecular mechanisms of cancer biology introduces targeted therapy as a complementary method along with other conventional therapies. Recombinant immunotoxins are tumor specific antibodies that their recognizing fragment is utilized for delivering modified toxins into tumor cells. These molecules have been considered as a targeted strategy in the treatment of human cancers. HER2 tumor biomarker is a transmembrane tyrosine kinase receptor that can be used for targeted therapies in the forms of anti-HER2 monoclonal antibodies, antibody–drug conjugates and immunotoxins. There have been many studies on HER2-based immunotoxins in recent years, however, little progress has been made in the clinical field which demanded more improvements. Here, we summarized the HER2 signaling and it’s targeting using immunotherapeutic agents in human cancers. Then, we specifically reviewed anti-HER2 immunotoxins, and their strengths and drawbacks to highlight their promising clinical impact.

Keywords